Gemina Laboratories Ltd.

OTC: GLABF · Healthcare · Biotechnology

Canadian filerHQ Burnaby, BCReports USD

#1102 of 1,394 Healthcare companies by revenue

EA Score

——

FH 24DQ —GM —SS 24

v0.1 · 35/100 weight · pillars only

↑ Piotroski F, market scale · ↓ operating margin, net margin

Methodology →

Revenue TTM

$15.3k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.7M

Employees

Market cap

$3.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$15.4k21.5k CAD2025

Net income-$1.7M-2.3M CAD2025

Operating income-$1.6M-2.2M CAD2025

Total assets$1.2M1.6M CAD2025

Liabilities$5.6M7.6M CAD2025

Equity-$4.4M-6.0M CAD2025

Revenue trend

FY2020 – FY2025 · USD

FY20

FY21

FY22

FY23

FY24

$15.4k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Gemina Laboratories Ltd. booked $15.4k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -10893.2% net margin.

Peers · Healthcare

Liminatus Pharma, Inc. Class A Common Stock——Decoy Therapeutics Inc.30D bioAffinity Technologies, Inc.31D Telesis Bio, Inc.——

Key facts

CEORobert Crandall Greene

SectorHealthcare

IndustryBiotechnology

HeadquartersBurnaby, BC

ExchangeOTC: GLABF

Employees6

IPO date2022-03-29

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.